

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application 10/522,426	Our File No. P/2107-264
	Applicant Ferdinand Hermann Bahlmann, et al.	
	Filing Date March 25, 2006	Group Art Unit 1654

U.S. PATENT DOCUMENTS (not submitted for applications filed after 6/30/03)

Examiner Initial	Document Number	Date MM-YYYY	Name	Class	Sub-class	Filing Date If Appropriate
	US-5,980,887	11-1999	Isner et al.			
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM-YYYY	Country	Class	Sub-class	Translation	
						Yes	No
	WO 89/07944	09-1989	WIPO/PCT			X	
	WO 98/10650	03-1998	WIPO/PCT			X	
	WO 00/61164	10-2000	WIPO/PCT			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Korean Office Action dated March 22, 2010 in corresponding Korean Patent Application No. 10-2005-7001341 (English language).
		N. D. Vaziri, et al., "Erythropoietin Enhances Recovery From Cisplatin-Induced Acute Renal Failure," American Journal of Physiology, Vol. 266, F360-F366 (1994).

Examiner	/Thomas Heard/	Date Considered	04/20/2010
----------	----------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/